<DOC>
	<DOCNO>NCT00929370</DOCNO>
	<brief_summary>The purpose study understand safety tolerability drug GSK1018921 14 day dose healthy volunteer patient volunteer .</brief_summary>
	<brief_title>A Repeat Dose Study With GSK1018921 Assess Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Healthy Volunteers Patients With Schizophrenia Evaluate Its Effect PK Midazolam .</brief_title>
	<detailed_description>This four part , parallel group , randomise , study evaluate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamic ( PD ) effect repeat dos GSK1018921 healthy volunteer stable patient schizophrenia evaluate effect pharmacokinetics midazolam . Part A evaluate 14 day repeat BID dose least three cohort healthy volunteer , assess safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) GSK1018921 . Part B study potential drug interaction GSK1018921 ( Maximum Tolerated Dose Part A ) midazolam 14 day repeat BID dose healthy volunteer therefore assess PK , safety tolerability . Part C single dose study healthy volunteer include CSF sample assess concentration GSK1018921 glycine CSF two dos ( 80 200 mg ) . Part D study stable patient schizophrenia , assess safety , tolerability , PK PD follow 28 day repeat BID dose . Safety assessment include physical examination , 12-lead ECGs , holter monitoring , vital sign , orthostatic vital sign , visual assessment , clinical lab test . Tolerability assess collect Adverse Events . PD assessment include glycine red blood cell , plasma CSF , well CogState Battery test , Visual Assessment Scale , Positive And Negative Symptom Scores ( PANSS ) Clinical Global Impression scale change .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>All subject ( Healthy Patients ) History drug alcohol abuse . Consumption drug , food drink affect CYP450 metabolism pathway . Has receive investigational drug within 30 day 5 half life twice duration biological effect drug ( ever longer ) . Donation blood excess 500mL within 56 day period . Patients eligibility Stable patient schizophrenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>GSK1018921</keyword>
	<keyword>GlyT-1 inhibitor</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>CSF</keyword>
	<keyword>Patient</keyword>
	<keyword>Midazolam</keyword>
</DOC>